Phase 3 Amlitelimab trial for atopic dermatitis to complete
Nov 11, 2025, 5:00:00 AM UTC
Summary
Sanofi is conducting a Phase 3, randomized, double-blind, placebo-controlled trial evaluating subcutaneous amlitelimab monotherapy in patients aged 12 and older with moderate-to-severe atopic dermatitis inadequately controlled by topical therapies. The study, with an enrollment of 601 participants, is expected to complete on November 11, 2025. Amlitelimab is a monoclonal antibody targeting OX40L, under development for inflammatory skin diseases. Trial results will inform potential regulatory submissions and future commercialization.
Company
SANOFI (SNY)NASDAQ — Healthcare: Manufacturing, Drug Manufacturers - General: Pharmaceutical Preparations
www.sanofi.comSimilar Events
Sanofi Phase 3 Amlitelimab Trial for Atopic Dermatitis Completion
Sanofi is expected to complete its Phase 3 clinical trial of amlitelimab, a subcutaneous monoclonal antibody therapy, for moderate-to-severe atopic dermatitis on December 11, 2025. The multinational, randomized, double-blind, placebo-controlled study (NCT06224348) evaluates efficacy and safety in patients aged 12 and older with inadequate response to topical treatments. Amlitelimab is being developed as a potential first-in-class therapy targeting OX40-Ligand for inflammatory skin diseases.
trial completionPhase 2 Study Completion of SAR444656 in Atopic Dermatitis
The Phase 2 clinical trial of SAR444656, sponsored by Sanofi, is expected to complete on August 18, 2026. The multinational, double-blind, placebo-controlled study is evaluating SAR444656 in adults with moderate to severe atopic dermatitis who are inadequately controlled with topical therapies or are candidates for systemic therapy. The trial aims to assess the safety and efficacy of multiple doses of SAR444656 versus placebo, with an enrollment target of 200 participants. SAR444656 is an investigational therapy for atopic dermatitis, a chronic inflammatory skin condition.
trial completionPhase 3 Sonelokimab Trial Completion for Hidradenitis Suppurativa
MoonLake Immunotherapeutics is conducting a Phase 3 clinical trial evaluating sonelokimab, a nanobody therapy, for moderate to severe hidradenitis suppurativa. The trial, enrolling 400 adults, is expected to complete on June 17, 2026. The study compares subcutaneous sonelokimab to placebo, with primary endpoints assessing efficacy and safety. Sonelokimab is a novel IL-17A/F inhibitor targeting inflammatory skin diseases. Successful results could support regulatory filings for this indication.
trial completionXmAb27564 Phase 1b Trial Completion Expected
Xencor is conducting a Phase 1b, randomized, double-blind, placebo-controlled multiple ascending dose study of XmAb27564 in adult patients with mild-to-severe plaque psoriasis and moderate-to-severe atopic dermatitis. The trial, which began in October 2022, is expected to complete by May 1, 2026. XmAb27564 is an investigational antibody targeting autoimmune skin diseases. The study will enroll approximately 128 patients and includes a one-year open-label extension for qualifying participants.
trial completion